Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating)'s share price crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $1.81 and traded as high as $2.54. Adaptimmune Therapeutics shares last traded at $2.38, with a volume of 567,183 shares.
Adaptimmune Therapeutics Price Performance
The firm has a market cap of $385.61 million, a PE ratio of -2.12 and a beta of 1.79. The stock's fifty day moving average price is $1.81 and its 200-day moving average price is $2.01.
Get Adaptimmune Therapeutics alerts:Institutional Investors Weigh In On Adaptimmune Therapeutics
A number of hedge funds have recently modified their holdings of the company. Alps Advisors Inc. purchased a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at about $163,000. JPMorgan Chase & Co. grew its holdings in shares of Adaptimmune Therapeutics by 5.3% in the second quarter. JPMorgan Chase & Co. now owns 1,474,163 shares of the biotechnology company's stock valued at $2,506,000 after purchasing an additional 74,398 shares during the period. Hunter Associates Investment Management LLC grew its holdings in shares of Adaptimmune Therapeutics by 42.5% in the second quarter. Hunter Associates Investment Management LLC now owns 28,500 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 8,500 shares during the period. Vigilare Wealth Management purchased a new stake in shares of Adaptimmune Therapeutics in the second quarter valued at about $71,000. Finally, Virtu Financial LLC purchased a new stake in shares of Adaptimmune Therapeutics in the first quarter valued at about $50,000.
About Adaptimmune Therapeutics
(Get Rating)Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.
Read More
- Get a free copy of the StockNews.com research report on Adaptimmune Therapeutics (ADAP)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.